FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946572257> ?p ?o ?g. }

• W2946572257 endingPage "5632" @default.
• W2946572257 startingPage "5632" @default.
• W2946572257 abstract "Abstract Introduction. The pronostic of Chronic hepatitis C (Hep C) has transformed towards cure in recent years with the advent of the antiviral treatment by SOFOSBUZIR (400mg/j) and DACLATASVIR (60mg/j) during 11 weeks usually turning HepC into a complete response (undetectable HCV viral load) or with HARVONI (LEDIPASVIR 90mg and SOFOSBUVIR 400mg) during 12 weeks. In parallel, Multiple Myeloma is a known hematological malignancy characterized with a very severe immuno deficiency status particularly of regards to hypogammaglobulinemia, but also recurrent short period of neutropenia, and often lymphopenia, induced by the various treatments available in the armamentarium of Myeloma. One treatment carries certainly the greatest risk of maximizing the global immunodepression of patients with Multiple Myeloma, that is the intensification using autologous transplantation conditionned with high dose melphalan (ASCT). Studies have demonstrated that the vaccination status of patients with Myeloma was severely impaired and that patients could develop infections particularly in the context of the autologous transplantation. We sought to study whether cured Hep C might relapse in patients with Myeloma while treated with induction, autologous transplantation and post transplant treatment phases. Method. We have reviewed 2 cases of MM plus Hep C homogeneously treated on a transplant eligible schema for MM and also treated using the most advanced cure for Hep C treatments. The 2 patients had a VTd- ASCT-VTd for MM treatment. The 2 patients were of genotype 4 Hep C, with the following viral loads, 1 966 055 UI/ml and 7 907 720/ml with normal hepatic enzymes. Results. AGE, sex ratio male, ISS-R was 1 and 3 (b2m elevated plus elevated LDH) respectively. None of the patients was diagnosed with either plasmablastic features, adverse cytogenetic (t(4 ;14) or del17p), PCL or EMD. MM Response prior to ASCT at completion of Induction was CR and PR, respectively. The 2 patients had undetectable viral loads prior to undergo ASCT. Interestingly, we noticed a relapse for one patient 1 month after ASCT (viral load 471 680 UI/ml), the second patient being pending at this timepoint. For the first patient in relapse for Hep C, a second Hep C treatment was started with VIEKIRAX and RIBAVIRINE during 12 weeks allowing the patient to enter again into complete response for Hep C. One year after this second treatment there is no relapse for HCV infection and for multiple myeloma. Conclusion. Autologous stem cell transplantation induces a major immunosuppression increasing the risk for HCV cure treatment failure. We have looked a tour series of patients and already identified one case with such issue, and possibly a second case to come. This data question on the need to use the Hep C cure treatment PRIOR to ASCT in patients with MM given the risk the cost issue and the risk of failure. This data question also the ability of the Hep C cure treatment to be given post ASCT with possibly a greater chance of success. This data must be confirmed on a larger international effort. Disclosures Leleu: Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Mundipharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2946572257 created "2019-05-29" @default.
• W2946572257 creator A5001388191 @default.
• W2946572257 creator A5002859307 @default.
• W2946572257 creator A5007570432 @default.
• W2946572257 creator A5013188968 @default.
• W2946572257 creator A5014335429 @default.
• W2946572257 creator A5015975130 @default.
• W2946572257 creator A5024174819 @default.
• W2946572257 creator A5024843240 @default.
• W2946572257 creator A5030870316 @default.
• W2946572257 creator A5031083574 @default.
• W2946572257 creator A5033496511 @default.
• W2946572257 creator A5034396355 @default.
• W2946572257 creator A5035255271 @default.
• W2946572257 creator A5036292176 @default.
• W2946572257 creator A5036356849 @default.
• W2946572257 creator A5039351913 @default.
• W2946572257 creator A5042086922 @default.
• W2946572257 creator A5044366775 @default.
• W2946572257 creator A5047928065 @default.
• W2946572257 creator A5048560248 @default.
• W2946572257 creator A5050460601 @default.
• W2946572257 creator A5051969245 @default.
• W2946572257 creator A5053225242 @default.
• W2946572257 creator A5054355051 @default.
• W2946572257 creator A5061191554 @default.
• W2946572257 creator A5062471839 @default.
• W2946572257 creator A5064113917 @default.
• W2946572257 creator A5068630847 @default.
• W2946572257 creator A5070507316 @default.
• W2946572257 creator A5074099703 @default.
• W2946572257 creator A5083876810 @default.
• W2946572257 creator A5086472455 @default.
• W2946572257 date "2018-11-29" @default.
• W2946572257 modified "2023-10-18" @default.
• W2946572257 title "Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma" @default.
• W2946572257 doi "https://doi.org/10.1182/blood-2018-99-115266" @default.
• W2946572257 hasPublicationYear "2018" @default.
• W2946572257 type Work @default.
• W2946572257 sameAs 2946572257 @default.
• W2946572257 citedByCount "0" @default.
• W2946572257 crossrefType "journal-article" @default.
• W2946572257 hasAuthorship W2946572257A5001388191 @default.
• W2946572257 hasAuthorship W2946572257A5002859307 @default.
• W2946572257 hasAuthorship W2946572257A5007570432 @default.
• W2946572257 hasAuthorship W2946572257A5013188968 @default.
• W2946572257 hasAuthorship W2946572257A5014335429 @default.
• W2946572257 hasAuthorship W2946572257A5015975130 @default.
• W2946572257 hasAuthorship W2946572257A5024174819 @default.
• W2946572257 hasAuthorship W2946572257A5024843240 @default.
• W2946572257 hasAuthorship W2946572257A5030870316 @default.
• W2946572257 hasAuthorship W2946572257A5031083574 @default.
• W2946572257 hasAuthorship W2946572257A5033496511 @default.
• W2946572257 hasAuthorship W2946572257A5034396355 @default.
• W2946572257 hasAuthorship W2946572257A5035255271 @default.
• W2946572257 hasAuthorship W2946572257A5036292176 @default.
• W2946572257 hasAuthorship W2946572257A5036356849 @default.
• W2946572257 hasAuthorship W2946572257A5039351913 @default.
• W2946572257 hasAuthorship W2946572257A5042086922 @default.
• W2946572257 hasAuthorship W2946572257A5044366775 @default.
• W2946572257 hasAuthorship W2946572257A5047928065 @default.
• W2946572257 hasAuthorship W2946572257A5048560248 @default.
• W2946572257 hasAuthorship W2946572257A5050460601 @default.
• W2946572257 hasAuthorship W2946572257A5051969245 @default.
• W2946572257 hasAuthorship W2946572257A5053225242 @default.
• W2946572257 hasAuthorship W2946572257A5054355051 @default.
• W2946572257 hasAuthorship W2946572257A5061191554 @default.
• W2946572257 hasAuthorship W2946572257A5062471839 @default.
• W2946572257 hasAuthorship W2946572257A5064113917 @default.
• W2946572257 hasAuthorship W2946572257A5068630847 @default.
• W2946572257 hasAuthorship W2946572257A5070507316 @default.
• W2946572257 hasAuthorship W2946572257A5074099703 @default.
• W2946572257 hasAuthorship W2946572257A5083876810 @default.
• W2946572257 hasAuthorship W2946572257A5086472455 @default.
• W2946572257 hasBestOaLocation W29465722571 @default.
• W2946572257 hasConcept C126322002 @default.
• W2946572257 hasConcept C159654299 @default.
• W2946572257 hasConcept C203014093 @default.
• W2946572257 hasConcept C2522874641 @default.
• W2946572257 hasConcept C2775999097 @default.
• W2946572257 hasConcept C2776364478 @default.
• W2946572257 hasConcept C2776408679 @default.
• W2946572257 hasConcept C2776455275 @default.
• W2946572257 hasConcept C2776694085 @default.
• W2946572257 hasConcept C2776979040 @default.
• W2946572257 hasConcept C2777063308 @default.
• W2946572257 hasConcept C2777805810 @default.
• W2946572257 hasConcept C2778390639 @default.
• W2946572257 hasConcept C2778684742 @default.
• W2946572257 hasConcept C2779050716 @default.
• W2946572257 hasConcept C2780040827 @default.
• W2946572257 hasConcept C2911091166 @default.
• W2946572257 hasConcept C71924100 @default.
• W2946572257 hasConcept C90924648 @default.
• W2946572257 hasConceptScore W2946572257C126322002 @default.
• W2946572257 hasConceptScore W2946572257C159654299 @default.
• W2946572257 hasConceptScore W2946572257C203014093 @default.

• next